Marseille, France, March 23, 2015 – HalioDx, created from a management buy-out of QIAGEN Marseille, today announces its inception. HalioDx ambition is to become the reference company in immuno-oncology diagnostics, moving personalized medicine forward.
A management buy-out by the QIAGEN Marseille Executive team
The ambition to become the reference diagnostic company in immuno-oncology
A business model combining immune companion diagnostics with biopharma